joint venture, Precedent Bloomfield Financial, LLC, Indianapolis, Indiana, in lending and leasing on manufacturing equipment, office equipment, and real estate up to \$500,000, pursuant to § §225.25(b)(1) and (5) of the Board's Regulation Y. The geographic scope for these activities is the State of Indiana.

Board of Governors of the Federal Reserve System, September 20, 1995. Jennifer J. Johnson,

*Deputy Secretary of the Board.* [FR Doc. 95-23923 Filed 9–26–95; 8:45 am] BILLING CODE 6210–01–F

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

[Docket No. 93D-0236]

## Gender Studies in Product Development, Scientific Issues and Approaches; Notice of a Public Workshop

**AGENCY:** Food and Drug Administration, HHS.

## ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a public workshop entitled "Gender Studies in Product Development: Scientific Issues and Approaches' is being held on November 6 and 7, 1995. The workshop will focus on issues related to FDA's guideline entitled 'Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs." The guideline provides guidance on FDA's expectations regarding inclusion of both genders in drug development. **DATES:** The public workshop will be held on November 6 and 7, 1995, from 7:30 a.m. to 4 p.m.; an opportunity for public comment is planned on November 6, 1995, from 2:15 p.m. to 3:15 p.m. Interested persons should register by October 23, 1995. Attendance will be limited based on the availability of seating. Submit written notices of participation by October 23, 1995. Time may be limited depending on the number of participants scheduled to speak.

ADDRESSES: The public workshop will be held at Doubletree Hotel, 1750 Rockville Pike, Rockville, MD 20852, 301–468–1100. Participants who wish to speak during the public comment session should request time by sending their name, affiliation, address, and phone number to John Sellman, Sociometrics, Inc., 8300 Colesville Rd., suite 550, Silver Spring, MD 20910, 301–608–2151, or FAX 301–608–3542. There is no registration fee, for this workshop. Those persons interested in attending the public workshop should mail their registration to Sociometrics, Inc. (address above). Copies of the transcript of the workshop summary will be available from the Freedom of Information Public Records and Documents Center (HFI–35), 5600 Fishers Lane, Rockville, MD 20057.

FOR FURTHER INFORMATION CONTACT: Mary C. Gross, Office of External Affairs (HF-60), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3364.

SUPPLEMENTARY INFORMATION: In the Federal Register of July 22, 1993 (58 FR 39406), FDA published a notice on a guideline entitled "Guideline for the Study and Evaluation on Gender Differences in the Clinical Evaluation of Drugs." The guideline discusses: Inclusion of patients of both genders in drug development; analyses of clinical data by gender; assessment of potential patient differences on the basis of gender, age, race, disease state, organ function, body size, genetic polymorphism and other characteristics that may affect responses to drugs, biologics or medical devices. The workshop will encourage an open scientific exchange in order to raise questions and issues related to the guideline.

Optimal treatment of patients in some instances, may depend on an awareness of the effect of these characteristics so that suitable adjustments may be made in dosage amount and dosage schedules. Questions have arisen, however, regarding the clinical trials that are needed or that can be developed to carry out appropriate gender analysis and detect important clinical differences in gender related responses. It is expected that by using gender as the model characteristic in this workshop, important information may be derived regarding patient characteristics that affect the safety and efficacy profile of medical products.

Dated: September 19, 1995. William B. Schultz, Deputy Commissioner for Policy. [FR Doc. 95–23996 Filed 9–26–95; 8:45 am] BILLING CODE 4160–01–F

#### National Institutes of Health

## National Institute of Environmental Health Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

*Name of Committee:* Environmental Health Sciences Review Committee.

Date: November 16-17, 1995.

Time: 8:30 a.m. to Adjournment.

*Place:* National Institute of Environmental Health Sciences, Building 101 Conference Rooms A, B, & C, South Campus, Research Triangle Park, North Carolina.

*Contact Person:* Dr. Ethel Jackson, Scientific Review Administrator, P.O. Box 12233, Research Triangle Park, NC 27709, (919) 541–7826.

*Purpose:* To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing; 93.115, Biometry and Risk Estimation; 93.894, Research and Manpower Development, National Institutes of Health.)

Dated: September 19, 1995.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 95–23902 Filed 9–26–95; 8:45 am] BILLING CODE 4140–01–M

#### Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Chemistry and Related Sciences.

Date: October 19, 1995.

*Time:* 1:00 p.m.

*Place:* NIH, Rockledge II, Room 5154, Telephone Conference.

*Contact Person:* Dr. Alec Liacouras, Scientific Review Administrator, 6701 Rockledge Drive, Room 5154, Bethesda, Maryland 20892, (301) 435–1740.

Name of SEP: Multidisciplinary Sciences. Date: October 30-November 1, 1995. Time: 8:00 p.m.

Place: Oklahoma City, Oklahoma. Contact Person: Dr. Marjam Behar, Scientific Review Administrator, 6701 Rockledge Drive, Room 5218, Bethesda,

Maryland 20892, (301) 435–1180.

*Name of SEP:* Clinical Sciences. *Date:* October 31, 1995.

49848

*Time:* 8:00 a.m.

Place: Holiday Inn, Bethesda, Maryland. Contact Person: Dr. Marjam Behar, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435–1783.

Name of SEP: Multidisciplinary Sciences. Date: November 1–3, 1995. Time: 8:00 p.m. Place: Urbana, Illinois.

*Contact Person:* Dr. Marjam Behar, Scientific Review Administrator, 6701

Rockledge Drive, Room 5218, Bethesda,

Maryland 20892, (301) 435–1180. *Name of SEP:* Clinical Sciences. *Date:* November 7, 1995.

*Time:* 1:00 p.m.

*Place:* NIH, Rockledge II, Room 4112, Telephone Conference.

Contact Person: Dr. Gopal Sharma,

Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda,

Maryland 20892, (301) 435–1783.

Name of SEP: Multidisciplinary Sciences. Date: October 10–13, 1995. Time: 7:30 p.m.

*Place:* Radisson Inn, West Lebanon, New Hampshire.

Contact Person: Dr. Donald Schneider,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5104, Bethesda, Maryland 20892, (301) 435–1165.

Name of SEP: Multidisciplinary Sciences. Date: October 16–17, 1995. Time: 8:00 a.m.

*Place:* Ramada Inn, Rockville, Maryland. *Contact Person:* Dr. Dharam Dhindsa,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5206, Bethesda, Maryland 20892, (301) 435–1174.

Name of SEP: Multidisciplinary Sciences. Date: October 19–20, 1995.

*Time:* 1:00 p.m.

*Place:* Doubletree Hotel, Rockville, Maryland. *Contact Person:* Dr. Harish Chopra,

Scientific Review Administrator, 6701 Rockledge Drive, Room 5112, Bethesda,

Maryland 20892, (301) 435–1169. *Name of SEP:* Clinical Sciences. *Date:* October 25, 1995.

*Time:* 8:00 a.m.

*Place:* Holiday Inn, Chevy Chase, Marvland.

*Contact Person:* Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda,

Maryland 20892, (301) 435–1783. Name of SEP: Multidisciplinary Sciences. Date: November 6–7, 1995. Time: 8:00 a.m.

Place: Wyndham Bristol Hotel,

Washington, DC. *Contact Person:* Dr. Marjam Behar, Scientific Review Administrator, 6701 Rockledge Drive, Room 5218, Bethesda, Maryland 20892, (301) 435–1180.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393– 93.396, 93.837–93.844, 93.846–93.878, 93.892, 93,893, National Institutes of Health, HHS)

Dated: September 20, 1995.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 95–23904 Filed 9–26–95; 8:45 am] BILLING CODE 4140–01–M

# Substance Abuse and Mental Health Services Administration

## Center for Substance Abuse Treatment National Advisory Council Meeting in September

**AGENCY:** Substance Abuse and Mental Health Services Administration (SAMHSA).

ACTION: Correction of meeting notice.

**SUMMARY:** Public notice was given in the Federal Register on September 7, 1995 (Vol. 60, No. 173, page 46623) that the Center for Substance Abuse Treatment National Advisory Council would be meeting on September 27 at the Rockwall II Building, 6th Floor Conference Room, 5515 Security Lane, Rockville, Maryland. The date of this meeting has subsequently been changed to September 26.

The agenda and hours of the open and closed sessions of the meeting and the contact for additional information remain as announced.

Dated: September 17, 1995.

Jeri Lipov,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 95–23892 Filed 9–22–95; 10:07 am] BILLING CODE 4162–20–P

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Housing-Federal Housing Commissioner

[Docket No. FR-3948-N-02]

#### **Notice of Debenture Recall**

**AGENCY:** Office of the Assistant Secretary for Housing-Federal Housing Commissioner, HUD. **ACTION:** Notice.

**SUMMARY:** This Notice announces a debenture recall of certain Federal Housing Administration debentures, in accordance with authority provided in the National Housing Act.

FOR FURTHER INFORMATION CONTACT: Richard Keyser, Room B133, Department of Housing and Urban Development, 451 Seventh Street SW., Washington, D.C. 20410, Telephone (202) 755–7510; TDD: (202) 708–4594). These are not toll-free numbers.

SUPPLEMENTARY INFORMATION: Pursuant to Section 207(j) of the National Housing Act, 12 U. S.C. 1713(j), and in accordance with HUD regulations at 24 CFR 207.259(e)(3), the Federal Housing Commissioner, with approval of the Secretary of the Treasury, announces the call of all Federal Housing Administration debentures except for those debentures subject to "debenture lock agreements," that have been registered on the books of the Federal Reserve Bank of Philadelphia, and are, therefore, "outstanding" as of September 30, 1995. The date of the call is January 1, 1996. To insure timely payment, debentures should be presented to the Federal Reserve Bank of Philadelphia by December 1, 1995.

The debentures will be redeemed at par plus accrued interest. Interest will cease to accrue on the debentures as of the call date. Final interest on any called debentures will be paid with the principal at redemption.

During the period from the date of this notice to the call date, debentures that are subject to the call may not be used by the mortgagee for a special redemption purchase in payment of a mortgage insurance premium.

No transfer or denominational exchanges of debentures covered by the foregoing call will be made on the books maintained by the Treasury Department on or after October 1, 1995. This does not affect the right of the holder of a debenture to sell or assign the debenture on or after this date. Payment of final principal and interest due on January 1, 1996, will be made to the registered holder or assignee.